
BACKGROUND:Ewing sarcoma is a rare malignancy of bone and soft tissue that most commonly affects children, adolescents, and young adults. Although multimodal treatment has improved survival in localised disease, outcomes remain poorer in adults, particularly in those with metastatic disease, larger tumours, or anatomically complex primary sites. Current staging systems are useful for treatment allocation but do not fully capture individual prognostic variation. This study aimed to develop and internally validate a predictive nomogram for disease-specific survival in adult patients with Ewing sarcoma. METHODS:A retrospective population-based cohort study was performed using the SEER-17 database from 2000 to 2015. Adult patients aged 18 years or older with histologically confirmed primary Ewing sarcoma of bone or soft tissue were included. The primary outcome was disease-specific survival. Predictor variables included age, sex, tumour site, tumour size, metastatic status, surgery, radiotherapy, and chemotherapy. Multivariable Cox proportional hazards regression was used to identify independent prognostic factors and construct a nomogram estimating 1-, 3-, and 5-year disease-specific survival. Internal validation was performed using 150 bootstrap resamples, and clinical utility was assessed using decision curve analysis. RESULTS:A total of 937 adult patients were included. The mean age was 33.9 years, and 556 patients were male. Extraosseous disease was the most common primary site, followed by axial bone and appendicular bone disease. Metastatic disease was present in 294 patients. Multivariable analysis identified metastatic disease, increasing age, larger tumour size, and absence of surgery as independent adverse prognostic factors. The nomogram incorporated age, clinical stage, primary site group, tumour size, surgery, and chemotherapy to estimate 1-, 3-, and 5-year disease-specific survival. Internal validation demonstrated an optimism-corrected C-index of 0.688, with acceptable calibration across the three time points. Decision curve analysis suggested that the full nomogram provided greater clinical utility than stage alone across intermediate threshold probabilities. CONCLUSION:This study developed and internally validated a population-based prognostic nomogram for adult patients with Ewing sarcoma. The model demonstrated acceptable discrimination and calibration, and may support individualised risk assessment, prognostic communication, and clinical decision-making. External validation in independent cohorts, incorporating molecular and treatment-intensity data, is required to further improve clinical applicability.
INTRODUCTION:In 2020, the American College of Surgeons introduced Operative Standard 5.8 mandating that lymph nodes be sampled from 1 hilar (N1) station and 3 separate mediastinal (N2) stations for all lung resections with curative intent. Though lymph node assessment is necessary for staging, there is limited data to define the number of lymph nodes or the extent of dissection. We seek to clarify modern trends in mediastinal lymph node sampling. METHODS:The SEER database was queried for patients who underwent surgery, 18 years and older, between 2018 and 2020 with non-small cell lung cancer. Demographics, stage, histology, and cause-of-death were compared. RESULTS:Of 17927 NSCLC patients, 16 431 (91.7%) underwent MLNS. Percentages increased over time 91% (2018), 92% (2019), and 93% (2020). MLNS was associated with more average harvested nodes (13.5 vs. 8.2), although the number of positive lymph nodes was similar. Death from any cause and lung cancer-specific death was higher in patients that did not receive MLNS (12.2% vs 9.1% and 7.8% vs 5.3%). CONCLUSION:MLNS is performed in more than 91% of anatomic resections. It is not known if each satisfied the 3N2 + 1N1 threshold with evidence strong enough to demand it. Operative Standard 5.8 mandates a solution for a problem that may not exist. Threatening hospitals with loss of accreditation distracts the surgeon agency with non-clinical considerations and compromises safe choices.
BACKGROUND:Neoadjuvant radiotherapy (RT) has been the standard of care for locally advanced rectal cancer (LARC) for over two decades. Adjuvant RT use in LARC represents a deviation from standard care and warrants further investigation. OBJECTIVES:To identify factors associated with adjuvant RT utilization. We hypothesized that sociodemographic determinants contribute to differences in the sequence of radiation treatment among patients with rectal cancer. METHODS:This retrospective cohort study utilized the National Cancer Database (2015-2022) to identify adults with clinical stage II-III rectal adenocarcinoma undergoing surgery and RT. Patients were categorized by RT sequence (neoadjuvant vs. adjuvant). Multivariable logistic regression identified factors associated with use of adjuvant RT. RESULTS:Of the included 48 452 patients, 6.9% received adjuvant RT. Compared with the neoadjuvant group, adjuvant RT recipients exhibited higher rates of pathologic upstaging (20.5% vs. 10.3%), positive margins (14.7% vs. 6.3%), and lymphovascular invasion (17.4% vs. 11.3%; all p < 0.001). On multivariable analysis, positive margins (aOR 1.78, 95% CI 1.43-2.22), lymphovascular invasion (aOR 1.96, 95% CI 1.66-2.31), upstaging (aOR 1.63, 1.31-2.02) were independently associated with adjuvant RT. CONCLUSIONS:Adjuvant RT appeared to be used in patients who were found to have high-risk tumor pathology postoperatively.
AIM:Standard treatment for muscle-invasive bladder cancer (MIBC) includes radical cystectomy (RC), a highly invasive procedure. We evaluated the utility of the Geriatric-8 (G8) screening tool in guiding treatment and whether the survival benefit of RC differs by G8 score. METHODS:We retrospectively reviewed patients with non-metastatic MIBC who underwent G8 assessment (2020-2024). Patients were grouped by G8: low (<11), intermediate (11-14), and high (>14). Treatment patterns and the effectiveness of RC were evaluated. RESULTS:A total of 152 patients were included (high: n = 55, intermediate: n = 67, low: n = 30). RC was performed in 124 patients (81.6%). Lower G8 was linked to older age, poorer performance status, and dependent instrumental activities of daily living (p < 0.01). Neoadjuvant chemotherapy followed by RC was more frequently planned in the high G8 group (81.8% vs. 53.7% vs. 26.7%, p < 0.0001), while immediate RC was a more common plan in the low G8 group (14.5% vs. 41.8% vs. 53.3%, p = 0.0003). RC was associated with significantly improved overall survival, and the benefit persisted after propensity score matching (p = 0.0013). Inverse probability of treatment weighting, which retained the whole cohort, gave a consistent estimate (hazard ratio [HR] 0.17, 95% confidence interval [CI] 0.08-0.39). Subgroup estimates were less precise in the low G8 group (HR 0.57, 95% CI 0.12-2.73) than in the intermediate (HR 0.14, 95% CI 0.06-0.33) and high (HR 0.10, 95% CI 0.02-0.39) groups. In sliding window analysis, HR estimates were higher at G8 < 9, with wide CIs. Similar results were observed for cancer-specific survival. CONCLUSIONS:RC was associated with a survival benefit in patients with intermediate and high G8 scores, whereas the evidence in the low G8 group was limited and inconclusive; careful risk-benefit evaluation remains warranted in this group.
BACKGROUND:Glossectomy for oral cancer can lead to significant concerns regarding speech and swallowing function. This study aims to assess the impact of age on post-glossectomy functional recovery and quality of life. METHODS:We conducted a retrospective analysis of patients who underwent glossectomy for primary oral cavity cancer involving the oral tongue from 2016 to 2024. Patients were stratified into three cohorts: < 60, 60-70, and > 70 years. Functional outcomes were assessed using speech-language pathology evaluations at 1 month, 6 months, 1 year, and 2 years postoperatively. Patient-reported quality of life was assessed using FACE-Q scores. RESULTS:206 patients were included, with 92 patients under 60, 61 patients aged 60-70, and 53 patients over 70. Primary closure was performed in 80 patients (39%), and free flap reconstruction in 109 (53%). One month postoperatively, patients over 70 demonstrated significantly higher rates of moderate to severe reductions in labial ROM and strength (p < 0.05). At 1 and 2 years, most functional differences had resolved, but deficits in labial ROM and strength persisted at 2 years (p = 0.048). FACE-Q scores, gastrostomy tube and tracheostomy dependence, length of stay, readmission, reoperation, and revision rates did not differ across cohorts. When adjusting for comorbidities, glossectomy type and age were significant predictors of long-term functional outcomes. CONCLUSION:Older patients undergoing glossectomy may experience initial delays in functional recovery, but long-term clinically meaningful functional outcomes are comparable across age groups. However, older patients may experience decreased patient-reported satisfaction in key domains, emphasizing the need for careful patient selection and shared decision-making when considering glossectomy in older adults.